Advocacy Toolkit

Overview
	This toolkit provides a one-stop resource for patients and patient groups interested in plasma protein therapies. Access the Patient Notification System, PPTA Fact Sheets, Issue Briefs, and connect with other patient groups and consumer organizations. The toolkit includes a wealth of information resources. An easy to follow format facilitates quick access to PPTA's efforts in both Europe and the U.S. Learn more about the Association's advocacy efforts to ensure patient access to therapies. You may use this information to frame your own advocacy efforts, educate your constituents, and strengthen your communications. If you have any questions or require additional information, contact us!
Resources Access to Care Patient Organizations Patient Information Resources Principles to Advance Patient Access to Care (10/4/2016) PPTA Charter for Working with External Groups
Resources for download Plasma Protein Therapies - Uniquely Saving Lives (available for Europe and North America) Download for Europe Europe Download for North America North America

Advocacy

PPTA News

HHS Launches Plasma and Blood Donation Campaign +

On August 4, the U.S. Department of Health and Human Services (HHS) launched a new nationwide campaign, Giving=Living, intended to draw awareness to the importance of plasma and blood donation, especially following a steep decline in both caused by the Covid pandemic.
Read More
PPTA Statement on the draft EU Substances of Human Origin Regulation +

PPTA welcomes positive developments but regrets missed opportunities to support plasma donors and patients who rely on plasma-derived medicinal products (PDMPs)

Brussels, Belgium (July 14, 2022). While the text of the draft regulation on Substances of Human Origin (SoHo) addresses a number of PPTA’s concerns, it has missed the opportunity to help Member States increase plasma collection to improve the reliable availability of life-saving, plasma-derived therapies to patients with a wide range of rare and complex, chronic diseases. As much as 38% of the plasma used to produce medicines for the EU’s 300,000 rare disease patients who rely on PDMPs comes from the U.S., a reliance highlighted during the pandemic, when critical plasma donations declined significantly.
Read More
Monkeypox Virus and Plasma Protein Therapies +

PPTA considers that the current MPXV outbreak is not a concern for the safety margins of plasma protein therapies manufactured by PPTA member companies. This assessment is also shared by other concerned parties (AABB, WHO).

Since May 2022, Monkeypox virus (MPXV) infections have been reported in non-endemic countries across Europe and North America (WHO, CDC, ECDC). People who use plasma protein therapies are understandably concerned about whether their therapies remain safe, with respect to MPXV. To address this issue, PPTA has summarized currently available facts.
Read More
Announcing PPTA’s New Global Chair +

It is with great pleasure that the Plasma Protein Therapeutics Association (PPTA) announces the election of Giles Platford from Takeda to the Chair of the PPTA Global Board.
Read More

1
2
3

› ‹

The Source, the international magazine of the plasma protein therapeutics industry, is published three times a year.

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives.
Find a Donation Center.

The need for plasma and plasma donors is more urgent than ever before. Visit givingplasma.org to learn more and to find a donation center near you.

"How Is Your Day?" is an initiative to raise awareness of the unique nature of plasma protein therapies and the value they provide to patients. It aims to inform and educate decision makers and the general public worldwide.

Get involved and follow "How Is Your Day?" on social media @HIYDglobal

Media and Information

Advocacy

Copyright © 2022 PPTA. All rights reserved. (202) 789-3100

Terms of Use | Privacy Statement | Sitemap